(Q44776685)

6 December 2017

Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study (English)

1 reference

6 December 2017

1 reference

4

1 reference

6 December 2017

8

1 reference

6 December 2017

12

1 reference

6 December 2017

A Mangia

1

1 reference

6 December 2017

G Spinzi

2

1 reference

6 December 2017

O Vuturo

3

1 reference

6 December 2017

A Iacobellis

5

1 reference

6 December 2017

M Piattelli

6

1 reference

6 December 2017

A Giacobbe

7

1 reference

6 December 2017

V Piermanni

9

1 reference

6 December 2017

G Minoli

10

1 reference

6 December 2017

G Montalto

11

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

Alimentary Pharmacology & Therapeutics

6 December 2017

1 reference

6 December 2017

19

1 reference

6 December 2017

331-337

1 reference

6 December 2017

3

1 reference

Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC).

6 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

Chronic hepatitis C with normal or abnormal aminotransferase levels: is it the same entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

Clinical management of HCV carriers with normal aminotransferase levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

Cholesterol and cholestasis: a lesson from the Mdr2 (-/-) mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

Updated definitions of healthy ranges for serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

Therapy of hepatitis C: patients with normal aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

Lamivudine resistance inimmunocompetent chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01844.X

10.1111/J.1365-2036.2004.01844.X

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference